Check category
Chronological Order:
WE ARE HIRING
Read more >>
Led by OrbiMed, HiRO Raised Tens of Millions of US Dollars in Series A Financing, to Offer Multinational Global Clinical Development Strategy
HiRO announced the completion of its Series A financing in the tens of millions of US dollars. This round of investment is led by OrbiMed, with the participation from existing shareholder, Fontus Capital.
Read more >>
PKU and HiRO Are Partnering to Bring Medicine to Patients, Faster and Successfully.
Read more >>
Seminar Advance Notice：DDI in Drug Development Seminar
On January 17, 2022, Hiro and the research ward of Beijing Friendship Hospital held a DDI seminar to jointly discuss the application of DDI research in new drug research and development, as well as the regulatory requirements and implementation case sharing of regulatory agencies for DDI research strategies.
Read more >>
HiRO completes the acquisition of PharmaSols, expands its coverage in the Asia-Pacific region, improves clinical operation capabilities and international layout
HiRO's acquisition of Pharmaceutical Solutions (PharmaSols or PSL), an agreement was formally signed in October 2021.
Read more >>
HiRO and CluePoints have reached a strategic cooperation to provide the most advanced RBQM expertise and services in the Chinese market
HiRO and CluePoints signed a partnership agreement to provide HiRO clients state-of-the-art Risk-Based Quality Management (RBQM) expertise and technical services in Greater China.
Read more >>
Previous page
1
Next page
×
搜索
Tel：+86 21 62191220
Email ：info@harvestiro.com
Add：33C2, Zhongyi Building,
No. 580 Nanjing West Road, Shanghai
Copyright © 2022 Harvest Integrated Research Organization 沪ICP备2021009006号
×
-
-
-
Contact information
Service hours:9:00 — 18:00
Contact number:
-
